ICBTRT Program 0401-2 WEB用 - UMIN...ri 1013 2016 inawa aan 18 19 S1-12 Synergistic Effects of...
13
April 10-13, 2016 Okinawa, Japan 15 PROGRAM Monday, April 11 8:00～8:10 Opening remarks Conference Chair: Ryo Nishikawa （Japan） 8:10～9:07 Session 1 Molecular Biology Moderator: Erwin Van Meir （USA） O-1 Genetically Engineered GBM Mouse Models: in vivo Expression of Mutated IDH1 （R132H） Gene Using the Sleeping Beauty Transposase System Maria G. Castro （USA） O-2 Pre-Clinical Efficacy of EZH2 Inhibition in the Genetically-Engineered IDH1 Wild-Type Proneural GBM Mice Fumiharu Ohka （Japan） O-3 Mutant IDH Expression Drives Htert Reactivation as Part of the Cellular Transformation Process Russell Pieper （USA） O-4 Therapeutic Vulnerability of IDH1 Mutant Gliomas to NAD+ Depletion Daniel P. Cahill （USA） O-5 Identifying Novel Vulnerabilities in Oxidative Stress Pathways in IDH1 Mutant Glioma Simone P. Niclou （Luxembourg） O-6 Mutant IDH1 Suppresses Local and Systemic Thrombosis in Glioma Patients Craig Horbinski （USA） O-7 ATRX Reduction Promotes Chemoresistance and Xenograft Growth in Glioblastoma Charles Eberhart （USA） O-8 ATRX Deficiency Promotes Invasive Behavior in Glioma Cells of Origin by Dysregulating Chromatin Accessibility and Modulating Gene Expression Jason T Huse （USA） O-9 Mitochondrial Metabolism Suppression by PGK1 Zhimin Lu （USA） O -10 Alternate Activation of the Pentose Phosphate Pathway and Glycolysis Are Intrinsic to the Proliferative/Migratory Glioma Phenotype - Independent from Hypoxia Katrin Lamszus （Germany） O -11 Inhibition of Hexokinase 2 Through Tumor Glycolysis Inhibitors Identified Through a Drug Screen Inhibits Glioblastoma Growth in vitro and in vivo Gelareh Zadeh （Canada） O -12 Non-Metabolic Function of Phosphofructokinase-1 in Glioblastoma Maintenance Petra Hamerlik （Danmark） O -13 Control of Glucose Uptake in Glioblastoma Cells Lorenzo Magrassi （Italy） O -14 Glucose-Dependent Mechanism of Targeted Cancer Therapy Resistance Kenta Masui （Japan） O -15 Coexpression of Fatty Acid Synthase （FASN） and Carnitine Palmitoyltransferase 1C （CPT1C） in Human Gliomas and Glioma Stem Cell Xenografts Tatsuya Abe （Japan） O -16 SCAP Integrates Oncogenic Signaling and Metabolism for Glioblastoma Growth Deliang Guo （USA）
Transcript of ICBTRT Program 0401-2 WEB用 - UMIN...ri 1013 2016 inawa aan 18 19 S1-12 Synergistic Effects of...
April 10-13, 2016 Okinawa, Japan
15
PROGRAM
Monday, April 11
8:00～8:10 Opening remarksConference Chair: Ryo Nishikawa （Japan）
8:10～9:07 Session 1 Molecular BiologyModerator: Erwin Van Meir （USA）
O-1 Genetically Engineered GBM Mouse Models: in vivo Expression of Mutated IDH1 （R132H） Gene Using the Sleeping Beauty Transposase SystemMaria G. Castro（USA）
O-2 Pre-Clinical Efficacy of EZH2 Inhibition in the Genetically-Engineered IDH1 Wild-Type Proneural GBM MiceFumiharu Ohka（Japan）
O-3 Mutant IDH Expression Drives Htert Reactivation as Part of the Cellular Transformation ProcessRussell Pieper（USA）
O-4 Therapeutic Vulnerability of IDH1 Mutant Gliomas to NAD+ DepletionDaniel P. Cahill（USA）
O-5 Identifying Novel Vulnerabilities in Oxidative Stress Pathways in IDH1 Mutant GliomaSimone P. Niclou（Luxembourg）
O-6 Mutant IDH1 Suppresses Local and Systemic Thrombosis in Glioma PatientsCraig Horbinski（USA）
O-7 ATRX Reduction Promotes Chemoresistance and Xenograft Growth in GlioblastomaCharles Eberhart（USA）
O-8 ATRX Deficiency Promotes Invasive Behavior in Glioma Cells of Origin by Dysregulating Chromatin Accessibility and Modulating Gene ExpressionJason T Huse（USA）
O-9 Mitochondrial Metabolism Suppression by PGK1Zhimin Lu（USA）
O-10 Alternate Activation of the Pentose Phosphate Pathway and Glycolysis Are Intrinsic to the Proliferative/Migratory Glioma Phenotype - Independent from HypoxiaKatrin Lamszus（Germany）
O-11 Inhibition of Hexokinase 2 Through Tumor Glycolysis Inhibitors Identified Through a Drug Screen Inhibits Glioblastoma Growth in vitro and in vivoGelareh Zadeh（Canada）
O-12 Non-Metabolic Function of Phosphofructokinase-1 in Glioblastoma MaintenancePetra Hamerlik（Danmark）
O-13 Control of Glucose Uptake in Glioblastoma CellsLorenzo Magrassi（Italy）
O-14 Glucose-Dependent Mechanism of Targeted Cancer Therapy ResistanceKenta Masui（Japan）
O-15 Coexpression of Fatty Acid Synthase （FASN） and Carnitine Palmitoyltransferase 1C （CPT1C） in Human Gliomas and Glioma Stem Cell XenograftsTatsuya Abe（Japan）
O-16 SCAP Integrates Oncogenic Signaling and Metabolism for Glioblastoma GrowthDeliang Guo（USA）
21st International Conference on Brain Tumor Research and Therapy
16 17
9:10～9:52 Session 2 Molecular Biology-2Moderator: Shi-Yuan Cheng （USA）
O-17 Redefining the Cellular Architecture of Human Gliomas Through Large-Scale Single-Cell AnalysesMario L. Suva（USA）
O-18 Drosophila Brat and Human Ortholog TRIM3 Regulate Asymmetric Cell Division in Brain Tumor Stem Cells Through Notch SignalingDaniel J. Brat（USA）
O-19 Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma NeurospheresManabu Natsumeda（Japan）
O-20 Glioma Stemness as a Moving Therapeutic TargetIchiro Nakano（USA）
O-21 Exploiting Exosomes from Human Bone Marrow Mesenchymal Stem Cells to Deliver Therapeutic microRNAs to GliomasFrederick F. Lang（USA）
O-22 Human Fat-Derived Mesenchymal Stem Cells Bioengineered to Secrete BMP4 Are Non-Oncogenic, Suppress Glioma, and Prolong SurvivalSara Ganaha（USA）
9:52～10:15 Coffee Break
10:15～11:30 Session 3 Molecular Biology-3Moderator: Ichiro Nakano （USA）
O-23 N-Cadherin Upregulation Mediates Adaptive Radioresistance in Glioma Stem CellsSatoru Osuka（USA）
O-24 Combined Targeted Inhibition of STAT3 and the Epigenetic Regulator LSD1 Sensitize Mesenchymal GBM Stem-Like Cells to RadiationHoward Colman（USA）
O-25 TIE2 Mediates DNA Repair in Brain Tumor Stem Cells Via Histone Phosphorylation and ABL1 RecruitingJuan Fueyo（USA）
O-26 Targeting the Tumor Microenvironment in GBMKarl H. Plate（Germany）
O-27 c-Met/β1 Integrin: A Receptor Complex Driving Invasive Resistance to Anti-Angiogenic TherapyManish K. Aghi（USA）
O-28 Cross-Talk of the Vascular Endothelial Growth Factor and Transforming Growth Factor-Beta Pathways in GlioblastomaMichael Weller（Switzerland）
O-29 SHP-2-Upregulated ZEB1 Is Important for Pdgfralpha-Driven Glioma Epithelian-Mesenchymal Transition and InvasionHaizhong Feng（CHINA）
O-30 IL-33 Orchestrates the Brain Tumor Microenvironment to Promote Glioma Progression and Therapeutic ResistanceDonna L. Senger（Canada）
O-31 The Role of Stress Granules in Astrocytoma Cell SignalingJames T. Rutka（Canada）
O-32 Tenascin C Is Developmentally Regulated by the PAX6 and DLX2 Homeobox Genes During Forebrain Development – Implications for Glioma InvasionDavid D. Eisenstat（Canada）
★
★15min (Presentation 13min + QA 2min)
April 10-13, 2016 Okinawa, Japan
16 17
O-33 NKG2D-Dependent Immune Surveillance Contributes to Anti-Tumor Effects of Chemotherapy and Radiotherapy Against GlioblastomaPatrick Roth（Switzerland）
O-34 EEF1A1-PLCG1 Axis Is a Novel Therapeutic Target Against Gliomas with Acquired Temozolomide Resistance or AdaptationArata Tomiyama（Japan）
O-35 EGFR Inhibitor Resistance Mechanisms in GBMJoanna J. Phillips（USA）
O-36 Up-Regulation of MSK1/β-Catenin Signaling Leads to Adaptive Resistance to PI3K/mTOR Inhibition in Human GlioblastomaW.K. Alfred Yung（USA）
O-37 ERK Inhibitors Show Efficacy Against BRAF-Mutant GliomasTheodore Nicolaides（USA）
O-38 PID1, a Brain Tumor Growth Inhibitor, Is a Novel Interacting Partner and Regulator of Critical Receptor Kinase SignalingAnat Erdreich-Epstein（USA）
O-39 Tyrosine Phosphorylation of Nuclear PTEN Promotes Therapeutic Resistance Through Enhanced DNA Damage RepairFrank Furnari（USA）
O-40 HuR Multimerization Is Oncogenic in GliomaLouis Nabors（USA）
O-41 Ionizing Radiation Induces BRCA1-Nuclear Export and Glioma Synthetic Lethality of PARP1 Inhibition in a P53-Dependent MannerFen Xia（USA）
O-42 A Regulatory Circuit of miR-125b/miR-20b and Wnt Signaling Controls GBM Phenotypes Through FZD6-Mediated PathwaysShi-Yuan Cheng（USA）
O-43 mRNA-Seq of Tumefaction-Educated Platelets （TEPs） as a Tool for Blood-Based Diagnosis and Monitoring of Cns LesionsPieter Wesseling（Netherlands）
11:33～12:15 Session 4 Other Biological IssuesModerator: Joseph Costello （USA）
O-44 A Glioblastoma Methylation Assay （GaMA） Developed from Genomic Analysis of Glioma Spheroid Cultures （GSCs） Predicts Response to Radiation TherapyErik P. Sulman（USA）
O-45 The Prognostic and Predictive Value of an Explant Assay of Gliomas in Response to TemozolomideDavid R. Macdonald（Canada）
O-46 Gene-Drug Association Screening-Guided Precision Neuro-Oncology: Implication of Spatiotemporal Heterogeneity in Glioblastoma GenomeDo-Hyun Nam（Korea）
O-47 Precision Medicine in Recurrent Glioblastoma: A Feasibility Trial Conducted by the Ivy Foundation Early Phase Clinical Trials ConsortiumMichael D. Prados（USA）
O-48 Personalizing the Treatment for Glioblastoma PatientsKerrie L. McDonald（Australia）
O-49 Identification of Cytotoxic Chemical HUP1 Against the Temozolomide-Resistant Glioblastoma-Initiating Cells by a High-Throughput Drug ScreeningToru Kondo（Japan）
O-50 Biomarkers of Glioblastoma Identified by Quantitative Proteomics with Swath Mass SpectrometryMitsutoshi Nakada（Japan）
21st International Conference on Brain Tumor Research and Therapy
18 19
O-51 Molecular-Guided Neoadjuvant Chemotherapy for GliomasHikaru Sasaki（Japan）
O-52 Circulating Tumor Cells in GlioblastomaManfred Westphal（Germany）
O-53 Non-Invasive Assessment of Glioblastoma Biology Using Circulating Tumor DNAColin Watts（UK）
O-54 Ultra-Early Detection of Gliomas with Serum Autoantibodies for Specific Glioma AntigensYasuo Iwadate（Japan）
O-55 Detection of D-2-Hydroxyglutarate in the Cerebro-Spinal Fluid of Glioma Patients with Mutant IDH1 GenesErwin Van Meir（USA）
12:30～13:30 Lunchtime Seminar 1 （Sponsor: MSD K.K.）Moderator: Kazuhiko Mishima （Japan）
LS-1 Receptor Tyrosine Kinase Signaling Underlies Tumor Growth Through Epigenome and Transcription Factor Network RemodelingWebster Cavenee（USA）
13:45～15:12 Session 5 Immunology （Sponsor: Toray Industries, Inc.）Moderator: Hideho Okada （USA）
S1-1 Bone Marrow T Cell Sequestration with GBMPeter E. Fecci（USA）
S1-2 Immunological Changes During Tumor Progression from Primary to Recurrent GlioblastomaChristel C. Herold-Mende（Germany）
S1-3 Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M MutationHideho Okada（USA）
S1-4 Third Generation CARs with Reduced IL-2 Signaling Overcome Treg Suppression and Mount a Therapeutic Response Against Established Solid TumorsGary Archer（USA）
S1-5 The CAR2Brain-Study: A Phase I Study of Local Therapy with ErbB2/Her2-Targeted NK Cells for Recurrent GlioblastomaJoachim P. Steinbach（Germany）
S1-6 Vaccination with Dendritic Cells Loaded with Cytomegalovirus Antigen in Patients with GBM and Associations with Overall SurvivalJohn H. Sampson（USA）
S1-7 Co-Stimulatory Molecules, OX40 and CD40, Augment the Efficacy of Tumor Lysate-Based Vaccines Against Malignant GliomasRyuta Saito（Japan）
S1-8 Phase I Clinical Trial of IDH1 Vaccine in Recurrent Low Grade GliomasGordana Vlahovic（USA）
S1-9 WT1 Peptide Vaccination for Glioblastomas; Survivals, Biomarkers and Response AssessmentsNaoya Hashimoto（Japan）
S1-10 Novel WT1 Peptide Vaccination for Newly Diagnosed Malignant GliomasTetsuya Ueba（Japan）
S1-11 Autologous Formalin Fixed Tumor Vaccine for Patients with Newly-Diagnosed Glioblastoma; From Concept to Double Blind Phase IIb/III trialYoshihiro Muragaki（Japan）
★15min (Presentation 13min + QA 2min)
★
★
April 10-13, 2016 Okinawa, Japan
18 19
S1-12 Synergistic Effects of Regulatory and Memory T Cell Modulation in Dendritic Cell-Based Immunotherapy: Impact of mTOR and NFkB PathwayYohei Mineharu（Japan）
S1-13 Therapeutical Doses of Temozolomide Inhibit IL-10 Production by Dendritic Cells and Enhance the CTL ResponseAkio Asai（Japan）
S1-14 Engineering the Brain Immune System to Recognize and Eliminate Brain Tumors: Ad-Flt3L and Ad-TK Reconstitute Brain Immunity to Recognize Neo-Antigens –Initial Reports on a Phase I Clinical TrialPedro R. Lowenstein（USA）
S1-15 A Phase I Study of a Personalized Neoantigen Cancer Vaccine with Radiotherapy Among MGMT Unmethylated, Newly Diagnosed Glioblastoma PatientsDavid Reardon（USA）
S1-16 Glioma Microenvironment-Derived CCL2 Recruits Regulatory T Cells and Myeloid-Derived Suppressor CellsMaciej S. Lesniak（USA）
S1-17 Phase I Study to Determine the MTD of a Recombinant Immunotoxin Targeting Wildtype EGFR and Mutant EGFRvIII in Recurrent Glioblastoma PatientsVidyalakshmi Chandramohan（USA）
S1-18 The Effect of Ttfields on T Cells Immune FunctionalityZvi Ram（Israel）
S1-19 Germline Mutations Predict Response of Recurrent Glioblastoma to Immune Checkpoint InhibitionUri Tabori（Canada）
15:12～15:30 Coffee Break
15:30～16:30 Special Lecture （Sponsor: Eisai Co., Ltd.）Moderator: Motoo Nagane （Japan）
SL-1 Targeting Essential Growth Drivers in CancerHiroyuki Mano（Japan）
16:45～17:48 Session 6 Viral and GenetherapiesModerator: Tomoki Todo （Japan）
O-56 Intratumoral Administration of an Oncolytic Polio/Rhinovirus Recombinant （PVSRIPO） Against Recurrent WHO Grade IV Malignant Glioma （MG）Annick Desjardins（USA）
O-57 Oncolytic Poliovirus Immunotherapy of Malignant GliomaMatthias Gromeier（USA）
O-58 Clinical Development of Oncolytic HSV-1 G47delta for GlioblastomaTomoki Todo（Japan）
O-59 Third Generation Oncolytic HSV-1 （G47delta） Is Efficacious Against Glioblastoma-Derived Cancer Initiating CellsYasushi Ino（Japan）
O-60 Toxicity Study of Lentiviral HSV-Tk Mediated Suicide Gene Therapy in the Rat BrainHrvoje Miletic（Norway）
O-61 Histone Deacetylase 6 Inhibition Enhances Oncolytic Viral Replication in GliomaE. Antonio Chiocca（USA）
O-62 Oncolytic Viral Therapy for Brain TumorsBalveen Kaur（USA）
★
★15min (Presentation 13min + QA 2min)
21st International Conference on Brain Tumor Research and Therapy
20 21
O-63 Cell-Based Oncolytic Virotherapy of Experimental GliomasGhazaleh Tabatabai（Germany）
O-64 Combination Viro-Immunotherapy with Checkpoint Inhibition to Treat Glioma, Based on Location-Specific Tumor ProfilingBrian Patrick O'Neill（USA）
O-65 Combination of Oncolytic Adenoviruses and Immune Checkpoint TargetingJuan Fueyo（USA）
O-66 A Super Gene Expression System Enhances the Antitumor Effects of Adenovirus-Mediated REIC/Dkk-3 Gene TherapyKazuhiko Kurozumi（Japan）
O-67 Enhanced Efficacy of Prodrug Activator Gene Therapy with a Retroviral Replicating Vector （Toca 511） Combined with RadiationMasamichi Takahashi（Japan）
O-68 Human iPSC for Cell-Based Gene Therapy of GliomasIsabelle M. Germano（USA）
O-69 Towards Clincal Development of an Autologous Stem-Cell Based Glioma Therapy Using iPSC-NSC Derivation MethodsNils Ole Schmidt（Germany）
17:48～18:06 Session 7Moderator: Kazuhiko Mishima （Japan）
PathologyO-70 Dual Color MGMT/CD45-HAM56 for Corrected Nuclear Counts in Glioblastoma
Roger E. McLendon（USA）
Other Clinical IssuesO-71 Multi-Centre Phase I Trial of the Proteasome Inhibitor Marizomib with Bevacizumab in Patients with
Progressive Glioblastoma （GBM）Warren P. Mason（Canada）
Pediatric-2O-72 High Diagnostic Value of Placental Alkaline Phosphatase Levels （PLAP）: A New Marker for
Intracranial Germ Cell TumorsYasuo Aihara（Japan）
Radiation Oncology/ImagingO-73 Creation of a Dual-Labeled Cancer-Targeting Alkylphosphocholine Analog for Dual Modality
Quantitative PET and Intraoperative Tumor VisualizationJohn S. Kuo（USA）
Surgery, etc.O-74 Sonodynamic Therapy Combined with a Photosensitizer, 5-Aminolevulinic Acid for Malignant Gliomas
Takanori Ohnishi（Japan）
April 10-13, 2016 Okinawa, Japan
20 21
Tuesday, April 12
8:00～9:09 Session 8 PediatricModerator: Nada Jabado （Canada）
O-75 Metastatic Dissemination of Medulloblastoma Is Through the Blood, and Is Mediated by CCL2Michael D. Taylor（Canada）
O-76 The Medulloblastoma Enhancer Landscape Reveals Subgroup-Specific Cellular OriginsPaul A. Northcott（USA）
O-77 Convergence of Bmi1 and Chd7 in the Pathogenesis of MedulloblastomaSilvia Marino（UK）
O-78 Integrative Clustering Reveals Distinct Biological Subtypes Within Medulloblastoma SubgroupsVijay Ramaswamy（Canada）
O-79 BAI1 Silencing Promotes Medulloblastoma Formation Through a P53 Dependent MechanismDan Zhu（USA）
O-80 Clinical Significance of PD-L1 and CD8 Expression in Human MedulloblastomaYoshiki Arakawa（Japan）
O-81 A Phase I Trial of P28, a Non-HDM2 Mediated Peptide Inhibitor of P53 Ubiquitination for Pediatric Patients Recurrent CNS TumorsStewart Goldman（USA）
O-82 Disruption of GABA Metabolism in MedulloblastomaJosh Neman（USA）
O-83 Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk MedulloblastomaKenneth Cohen（USA）
O-84 Four New Brain Tumor Entities Emerge From Molecular Classification of CNS PNETsMarcel Kool（Germany）
O-85 C11orf95-RELA Fusion Alone is Sufficient to Form Human Supratentorial Ependymoma-Like Tumor in MiceTatsuya Ozawa（USA）
O-86 Outcome of Young Children with Supratentorial Ependymoma Treated with Radical Surgical Resection and Intensive Chemotherapy: The Head Start Ⅰ-Ⅲ Trials, 1991-2009Jonathan L. Finlay（USA）
O-87 Clinicopathological Features of Atypical Teratoid/Rhabdoid Tumor-Like Embryonal Tumors with Retained INI1 and BRG1 ExpressionJunko R. Hirato（Japan）
O-88 Heterogeneity in SWI/SNF Complex Compenents in Atypical Teratoid Rhabdoid TumorsAlexander R. Judkins（USA）
O-89 Atypical Teratoid/Rhabdoid Tumor （AT/RT） Arising from Ependymoma: A Type of Secondary AT/RTSumihito Nobusawa（Japan）
O-90 Establishment of a Nationwide Molecular Diagnostic Network for Pediatric Malignant Brain Tumors in JapanYonehiro Kanemura（Japan）
★15min (Presentation 13min + QA 2min)
★
21st International Conference on Brain Tumor Research and Therapy
22 23
9:12～10:24 Session 9 Pediatric-2Moderator: Torsten Pietsch （Germany）
O-91 Cellular Origin of Central Nervous System Germ Cell TumorsKoichi Ichimura（Japan）
O-92 Expression Profiling of Intracranial Germ Cell Tumors Reveals Upregulation of RAS Through mRNA-microRNA Signaling PathwayChing C. Lau（USA）
O-93 Dose-Reduced Radiotherapy with Platinum-Based Chemotherapy Has Improved Quality of Life in the Long-Term Survivors with GerminomaKazuhiko Sugiyama（Japan）
O-94 MicroRNA 372-373 in Cerebrospinal Fluid Is Potential Tumor-Derived Biomarkers for CNS Germ Cell TumorsKeita Terashima（Japan）
O-95 Long-Term Survival with Multimodal Therapy; Surgery, Carboplatin Based Chemotherapy Followed by Radiotherapy in Patients with Primary Intracranial Germ Cell TumorsKazuya Motomura（Japan）
O-96 Management of Intracranial Germ Cell Tumors – International Consensus and DifferencesUte Bartels（Canada）
O-97 Pediatric Low-Grade Glioma Molecular Stratification and Long Term ImplicationsCynthia E. Hawkins（Canada）
O-98 Type Ⅱ Raf Inhibitors as Targeted Therapeutics for Pediatric Low-Grade AstrocytomaMark W. Kieran（USA）
O-99 The Prognostic Factors of Pilocytic Astrocytoma in Children: A Retrospective Review of 16 CasesKentaro Chiba（Japan）
O-100 Functional Diversity and Co-Operativity Between Subclonal Populations of Paediatric Glioblastoma and Diffuse Intrinsic Pontine Glioma CellsChris Jones（UK）
O-101 Functional Dissection of the H3.3K27M MutationOren Becher（USA）
O-102 Histopathological WHO Grading and H3.3K27 Mutational Status Represent Independent Prognostic Markers in Pediatric High Grade GliomasTorsten Pietsch（Germany）
O-103 Spatial and Temporal Homogeneity of Driver Mutations in Diffuse Intrinsic Pontine GliomaNada Jabado（Canada）
O-104 Targeting Enzymatic Modifiers of Histone H3 K27 for Treating DIPGCharles David James（USA）
O-105 PNOC-003: Precision Medicine Trial for Children with Diffuse Intrinsic Pontine GliomaSabine Mueller（USA）
O-106 Microenvironment and Tumor Cell Expansion in Diffuse Intrinsic Pontine GliomaJavad Nazarian（USA）
O-107 Home-Based Palliative Care for Children with Recurrent and/or Refractory Cen Tral Nervous System TumorTakaaki Yanagisawa（Japan）
10:24～10:50 Coffee Break
★
★15min (Presentation 13min + QA 2min)
April 10-13, 2016 Okinawa, Japan
22 23
10:50～12:29 Session 10 Molecular Genetics （Sponsor: Nobelpharma Co., Ltd.）Moderator: Koichi Ichimura （Japan）
S2-1 Novel Brain Tumor Subtypes Identified by Genome-Wide Methylome ProfilingDavid T.W. Jones（Germany）
S2-2 Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaRoeland GW Verhaak（USA）
S2-3 Genome-Wide Methylation Analysis Identifies Genomic DNA Demethylation During Malignant Progression of GliomasAkitake Mukasa（Japan）
S2-4 Genome and Epigenome Perspectives of Human Brain Tumor EvolutionJoe Costello（USA）
S2-5 De Novo Transcriptome Assembly Finds Novel Glioblastoma Subtype-Specific TranscriptsBernhard Radlwimmer（Germany）
S2-6 High-Throughput Screening （HTS） of Glioma Stem-Like Cells （GSCs） Identifies Genomic Correlates of Therapeutic Response to Targeted TherapyJohn de Groot（USA）
S2-7 Genomic Tests Accurately Classify Gliomas into Five Molecular Groups and Provide Additional Information on Acquired Alterations and Clinical OutcomeRobert B. Jenkins（USA）
S2-8 ATRX and TERT Assays Provide Complementary Information in Adults with IDH-Mutated GliomaKyle M. Walsh（USA）
S2-9 Molecular Classification Based on IDH and TERT Identified Four Clinically Distinct Subclasses: A Study of Glioma Molecular Classification ConsortiumHideyuki Arita（Japan）
S2-10 Mutations in IDH1, IDH2, and in the TERT Promoter Define Clinically Distinct Subgroups of Adult Malignant GliomasHai Yan（USA）
S2-11 Preliminary Results of Phase I Study of AG-120, an Inhibitor of the IDH1 Mutant Protein, in Patients with IDH1-Mutant Solid Tumors, Including GliomasPatrick Y. Wen（USA）
S2-12 Detection of IDH1 Mutations in vivo by Magnetic Resonance Spectroscopy of Glutamate and 2-Hydroxyglutarate in Human Brain GliomasKazuhiro Tanaka（Japan）
S2-13 NGS-Based MSK-IMPACT Analysis Reveals Specific Genetic Alterations in Recurrent GlioblastomaShinya Tanaka（Japan）
S2-14 Genetic Biomarkers to Predict Prognosis and Kinetics of Clonal Evolution by Mathematical Computational Modeling in Low-grad GliomaAtsushi Natsume（Japan）
S2-15 Malignant Transformation in Oligodendroglioma with 1p19q LOHHideo Nakamura（Japan）
S2-16 Treatment Strategy for Grade II-III Gliomas Could Be Determined by IDH and TP53 StatusYuichi Hirose（Japan）
S2-17 Genetic and Histological Stability of 1p/19q Co-Deleted Gliomas at RecurrenceKeisuke Ueki（Japan）
S2-18 Co-Polysomy of Chromosomes 1 and 19 Predict Early Recurrence Among Non-1p/19q-Deleted Low-Grade GliomasRachel Grossman（USA）
S2-19 HDAC7 as a Possible Therapeutic Target for Mesenchymal GlioblastomaKoji Yoshimoto（Japan）
★
★
★15min (Presentation 13min + QA 2min)
21st International Conference on Brain Tumor Research and Therapy
24 25
S2-20 G Protein-Coupled Receptor 158: A Potential Prognostic Biomarker in GliomasSebastian Brandner（UK）
S2-21 Statistical Considerations for Developing Classification Models in GliomaAnnette M. Molinaro（USA）
S2-22 Evolution of Molecular Drivers in Glioblastomas During Temozolomide TreatmentTracy Batchelor（USA）
S2-23 Intraoperative Detection of IDH1 Mutations in Diffuse GliomasTakashi Komori（Japan）
12:35～12:56 Session 11 PathologyModerator: Takashi Komori （Japan）
O-108 Detection of P53 Mutations in Proliferating Vascular Cells in Glioblastoma MultiformeHideo Takeshima（Japan）
O-109 Practical Utility of Nestin and Olig2 as Immunohistochemical Markers for GliomasHideaki Yokoo（Japan）
O-110 Expression of Multidrug Resistant Genes in the Human GlioblastomasTakashi Tamiya（Japan）
O-111 Clinical and Pathological Characteristics of Adult Diffuse Brainstem GliomaShota Tanaka（Japan）
O-112 Microtube Networks Constitute a Major Resistance Factor in GliomasWolfgang Wick（Germany）
O-113 Tumor-Associated Macrophages and Microvascular Proliferation in GlioblastomaAtsushi Sasaki（Japan）
O-114 M2a-type Macrophages in Glioblastoma Are Characterized by Up-Regulation of ALDH1A2Waldemar Debinski（USA）
13:00～14:00 Lunchtime Seminar 2 （Sponsor: Chugai Pharmaceutical Co., Ltd.）Moderator: Keisuke Ueki （Japan）
LS-2 The New WHO Classification of Brain TumorsArie Perry（USA）
April 10-13, 2016 Okinawa, Japan
24 25
Wednesday, April 13
8:00～8:27 Session 12 Radiation Oncology/ImagingModerator: Susan Chang （USA）
O-115 Magnetic Resonance Analysis of Malignant Transformation in Recurrent GliomaSusan M. Chang（USA）
O-116 Magnetic Resonance Spectroscopy Detection of High Lipid Levels in Intraaxial Tumors Without Central Necrosis: A Characteristic of Malignant LymphomaKaoru Kurisu（Japan）
O-117 Diagnostic Possibility of Positron Emission Tomography Using [18F]Fluciclovine to Diagnose and to Delineate GliomasToshihiko Wakabayashi（Japan）
O-118 A Prospective Multicenter Single-Arm Clinical Trial of Bevacizumab for Patients with Surgically Untreatable Symptomatic Brain Radiation NecrosisShin-ichi Miyatake（Japan）
O-119 A Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant GliomaJennifer L. Clarke（USA）
O-120 Hypo-Fractionated IMRT with TMZ for GBMs -Tailor-Made Setting of Treatment Doses Owing to MGMT-Methylation Status-Toshihiko Iuchi（Japan）
O-121 Gamma Knife Radiosurgery for Brain Metastases from Pulmonary Large Cell Neuroendocrine Carcinoma （LCNEC）: Report of a Japanese Multi-Institutional Co-Operative Study （JLGK 1401 Study）Takuya Kawabe（Japan）
8:30～9:30 Special Seminar （Sponsor: Southern Tohoku General Hospital）Moderator: Yoko Nakasu （Japan）
ES1-1 Proton Beam Radiotherapy for Intracranial TumorsYasuhiro Kikuchi（Japan）
ES1-2 BNCT for the Treatment of Malignant Brain Tumors in Comparison with Other Particle RadiationShin-ichi Miyatake（Japan）
9:40～10:00 Coffee Break
10:00～10:51 Session 13 Other TumorsModerator: Kazuhiko Mishima （Japan）
O-122 Genomic Characterization of Primary Central Nervous System LymphomaMotoo Nagane（Japan）
O-123 Reduced Neurotoxicity with Methotrexate-Based Multiagent Chemotherapy （M-CHOP） and Deferred Radiotherapy for Primary Central Nervous System LymphomaTomotsugu Ichikawa（Japan）
O-124 Prognostic Impact of Completion of Initial High-Dose Methotrexate Therapy on Primary Central Nervous System Lymphoma: A Single Institution ExperienceKeishi Makino（Japan）
O-125 PCNSL: A Single-Centre Experience of Unselected Cases Treated with MTX Monotherapy and High-Dose Chemotherapy with Autologous Stem-Cell TransplantYoko Nakasu（Japan）
21st International Conference on Brain Tumor Research and Therapy
26 27
O-126 Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic TargetsPriscilla K. Brastianos（USA）
O-127 CD15 Is a Key Player in Non-Small Cell Lung Cancer Brain Metastasis and Is Regulated by Fut-7/4 Enzymes and Cell CycleGeoffrey J. Pilkington（UK）
O-128 Beta-Sitosterol Causes a Broad Spectrum Suppression of Melanoma Brain MetastasisRolf Bjerkvig（Norway）
O-129 NEO212: A New Drug for Triple Negative Breast Cancer Metastasis to BrainThomas C. Chen（USA）
O-130 CpG Methylation Profiling of MeningiomaKenneth D. Aldape（USA）
O-131 Meningioma Tumor Volume Correlation with MIB-1 Index, Microvascular Density and Patient OutcomeRandy L. Jensen（USA）
O-132 177Lu-DOTATATE/90Y-DOTATOC Peptide Receptor Radionuclide Therapy in Treatment Refractory Progressive MeningiomaJoerg C. Tonn（Germany）
O-133 The Somatic Landscape of SchwannomaSameer Agnihotri（USA）
O-134 Web-Based Efforts to Study Brain TumorsElizabeth B. Claus（USA）
10:54～11:12 Session 14 Surgery, etc.Moderator: Takamitsu Fujimaki （Japan）
O-135 The Use of Clinical fMRI in Brain Tumor Surgery PlanningJoseph Megyesi（Canada）
O-136 A Prospective Phase Ⅱ Clinical Trial of 5-Aminolevulinic Acid to Correlate Intratoperative Flouresence Intensity with Histologic CellularityMitchel S. Berger（USA）
O-137 Early Postoperative Expansion of Parenchymal High-Intensity Areas on T2-Weighted Imaging and Delayed Cerebral Edema After Carmustine Wafer Implantation for High-Grade GliomaEiichi Ishikawa（Japan）
O-138 Safety and Efficacy of BCNU Wafers in the Treatment of Japanese Glioma PatientsYukihiko Sonoda（Japan）
O-139 Efficacy and Adverse Events of Carmustine Wafers Implantation for the Treatments of High Grade Gliomas in a Single InstituteToshihiro Kumabe（Japan）
O-140 Initial Experience in a Pilot Study of Blood-Brain Barrier Opening for Chemo-Drug Delivery to Brain Tumors by MR-Guided Focused UltrasoundJames Perry（Canada）
April 10-13, 2016 Okinawa, Japan
26 27
11:15～11:39 Session 15 Other Clinical IssuesModerator: Joachim Steinbach （Germany）
O-141 A Complete National-Based Registration of Primary Tumours Support a Fair and Optimal Management of High International StandardRoger Henriksson（Sweden）
O-142 Sex-Specific Transcriptional Networks Underlie Sex Differences in GBM BiologyJoshua B. Rubin（USA）
O-143 Health-Related Quality of Life in Long-Term Survivors with Grade II Gliomas: The Contribution of Disease Recurrence and Karnofsky Performance StatusYoshiko Okita（Japan）
O-144 Clinicopathological Study of Long Survivors of Glioblastoma （GBM） – Multiinstitutional Retrospective SurveyTakamitsu Fujimaki（Japan）
O-145 Favorable Outcome of 1p/19q Co-Deleted Anaplastic Oligodendroglial Tumors Treated with PAV Chemotherapy Without Radiation TherapyTomoo Matsutani（Japan）
O-146 Phase I/II Study of a Combination of Temozolomide with ACNU for Ptaients with Recurrent Malignant GliomasTomokazu Aoki（Japan）
O-147 The Importance of Early Diagnosis and Treatment in GlioblastomasYoshitaka Narita（Japan）
O-148 Molecular Subgroup Analysis of EORTC 26082 （Phase 2） Temsirolimus and RT Versus TMZ/RT->TMZ in Patients with MGMT Unmethylated Newly Diagnosed GBMMonika E. Hegi（Switzerland）
11:45～12:45 Lunchtime Seminar 3 （Sponsor: Novocure Ltd.）Moderator: Ryo Nishikawa （Japan）
LS-3 Tumor Treating Fields – How to Integrate This Novel Modality in Clinical Trials for GlioblastomaRoger Stupp（Switzerland）
12:50～ Closing remarksConference Chair: Ryo Nishikawa （Japan）, Next Conference Chair: Rolf Bjerkvig （Norway）
